Department of Dermatology, Nippon Medical School, Tokyo, Japan.
Department of Dermatology, Housui Medical Clinic, Sapporo, Japan.
J Dermatol. 2018 Jun;45(6):727-731. doi: 10.1111/1346-8138.14225. Epub 2018 Jan 21.
Psoriasis is a chronic, relapsing, inflammatory keratotic skin disease. To elucidate the medication adherence and treatment satisfaction, we performed a questionnaire survey using the eight-item Morisky Medication Adherence Scale (MMAS-8) and nine-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) of 163 psoriatic patients who regularly visited hospitals or clinics. To assess the relationship between the MMAS-8/TSQM-9 outcomes and severity of psoriasis, two different clinical severity indices were used: the Psoriasis Area and the Severity Index (PASI) for disease severity and the Psoriasis Disability Index (PDI) for quality of life (QOL) impairment. The MMAS-8 score for oral medication was significantly higher than that for topical medication. The oral and topical MMAS-8 scores were significantly correlated with the PDI score, but not with the PASI score, indicating that QOL impairment lowered treatment motivation. All of the TSQM-9 domain scores (effectiveness, convenience and global satisfaction) were significantly correlated with both the PASI and PDI scores, suggesting that patients whose skin and QOL conditions were under good control had high satisfaction with treatment. Patients treated with biologics had higher satisfaction than those treated with non-biologics.
银屑病是一种慢性、复发性、炎症性角化性皮肤病。为了阐明患者的用药依从性和治疗满意度,我们使用 8 项 Morisky 用药依从性量表(MMAS-8)和 9 项药物治疗满意度问卷(TSQM-9)对 163 例定期到医院或诊所就诊的银屑病患者进行了问卷调查。为了评估 MMAS-8/TSQM-9 结果与银屑病严重程度之间的关系,我们使用了两种不同的临床严重程度指数:用于评估疾病严重程度的银屑病面积和严重程度指数(PASI)和用于评估生活质量(QOL)损害的银屑病残疾指数(PDI)。口服药物的 MMAS-8 评分明显高于外用药物。口服和外用 MMAS-8 评分与 PDI 评分显著相关,但与 PASI 评分无关,这表明 QOL 损害降低了治疗动机。所有 TSQM-9 领域评分(有效性、便利性和总体满意度)均与 PASI 和 PDI 评分显著相关,表明皮肤和 QOL 状况得到良好控制的患者对治疗的满意度较高。接受生物制剂治疗的患者满意度高于接受非生物制剂治疗的患者。